#High Throughput Screening Market Share | Explore Tumblr posts and blogs

blog-site-for-market-research · 1 year ago

Text

Global High Throughput Screening Market Size| Growth | Scope, 2032

Market Overview

The global high throughput screening market is expected to mature at a 7.5% CAGR during the forecast period.

Market Highlights

High throughput screening has achieved mainstream acceptance over the past two decades and has become a traditional drug discovery tool in the pharmaceutical industry. Factors such as technical developments in HTS and rising pharmaceutical R&D spending are driving the global high throughput screening industry. In addition, demand development is projected to be powered by the growing research activities in stem cells & toxicology and emerging markets. In recent years, technological developments such as liquid handling automation, the development of novel technology systems, and computational methods to deal with vast volumes of data have increasingly powered the global demand for high-performance screening instruments. Rising rivalry for pioneering drug development and marketing demand for high-performance screening instruments among pharmaceutical firms is growing at a rapid rate.

Strong capital spending, on the other hand, is expected to hamper demand growth during the projected period. In addition, the high time consumption and high cost of high-throughput screening techniques can impede the growth of the market.

Segmental Analysis

Based on product & service, technology, applications, end user, and region, the global high throughput screening market has been segmented.

The global market has been bifurcated into reagents & assay kits, instruments, consumables & accessories, software and services, based on product & service.

Due to the large number of reagents and assay kits used in HTS techniques and increased government funding for life science research, the reagents & assay kits segment is expected to hold a significant share in the market.

Segmental Analysis

The worldwide market is divided into cell-based assays, 2D cell culture, 3D cell culture, 3D cell culture, perfusion cell culture, laboratory-on-a-chip (LOC), ultra-high-throughput screening, bioinformatics, and label-free technology based on technology.

Based on use, the global market is segmented into target recognition & confirmation, primary and secondary screening, toxicology assessment, and others. Due to rising pharmaceutical R&D and the increasing prevalence of many diseases, the application category is projected to be the fastest-growing.

The global market is categorised into pharmaceutical and biotechnology firms, university and government agencies, contract research organisations, and others, depending on end users.

Regional Overview

North America and Latin America have been segmented into the high-performance scanning industry in the Americas, with the North American market split into the US and Canada.

Due to the rising per capita healthcare spending and the fast penetration of advanced technologies in the region, the demand in the Americas is projected to dominate the global high throughput screening market. It is expected that the will adoption of HTS in the US and Canada will fuel the growth of the sector. In addition, growing spending on research by healthcare institutions is expected to boost demand growth in this field.

In Europe, the market was projected to see a substantial amount of growth. The existence of a well-established healthcare sector and the participation of main corporations can be attributed to this.

Leading to a rise in chronic diseases and rising government measures for health care reforms, the Asia-Pacific market is expected to have a steady growth rate during the forecast period.

The Middle East & Africa market is estimated to account for the lowest share of the global market because of the region's low per capita disposable income.

Competitive Dashboard

The key players operating in the global high throughput screening market research are Aurora Biomed Inc. (Canada), Danaher (US), PerkinElmer (US), Tecan (Switzerland), Hamilton (US), Axxam (Italy), Merck Group (Germany), Corning (US), BioTek (US), Beckman Coulter, Inc. (US), Agilent Technologies Inc. (US), Luminex Corporation (US), and Roche (Switzerland).

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]

Website: https://www.marketresearchfuture.com

#High Throughput Screening Market #High Throughput Screening Market Research #High Throughput Screening Market Size #High Throughput Screening Market Share #High Throughput Screening Market Report

1 note · View note

marketresearch258 · 1 day ago

Link

0 notes

tbrc34 · 2 days ago

Text

Liquid Handling System Market 2025-2033: Precision and Efficiency in Labs

Liquid Handling System Market plays a pivotal role in scientific advancements, enabling precise liquid measurement and transfer in laboratories worldwide. These systems are integral to sectors like pharmaceuticals, biotechnology, and academic research, supporting applications such as drug discovery, genomics, and clinical diagnostics.

To Request Sample Report : https://www.globalinsightservices.com/request-sample/?id=GIS20834 &utm_source=SnehaPatil&utm_medium=Article

Among the market segments, automated liquid handling systems dominate with a 45% share, driven by their unmatched precision and efficiency in high-throughput screening. Manual pipettes retain their relevance, accounting for 30% of the market, thanks to their affordability and versatility in smaller laboratories. The semi-automated systems segment holds 25%, bridging the gap between cost and automation needs.

North America leads the market, benefiting from robust R&D investments and a significant presence of pharmaceutical and biotech firms. Europe, with its established healthcare infrastructure, follows closely, with Germany spearheading innovation. The Asia-Pacific region is poised for rapid growth, propelled by expanding healthcare investments and research activities in countries like China and India.

In 2023, the market volume was estimated at 800 million units, projected to reach 1.2 billion units by 2033. Key players such as Thermo Fisher Scientific, Eppendorf AG, and Mettler Toledo are driving market dynamics through innovations like integrated solutions and user-friendly interfaces.

Regulations, including FDA guidelines and ISO standards, shape market strategies, emphasizing compliance and quality assurance. Future growth will be fueled by investments in automation, AI, and machine learning, enhancing accuracy and operational efficiency. Despite challenges like high initial costs and system complexities, the market holds promising opportunities in digitization and customization services.

#LiquidHandling #LaboratoryInnovation #PrecisionScience #DrugDiscovery #AutomationTech #BiotechTools #GenomicsResearch #AIInLabs #ScientificAdvancements #PharmaTech #LabEquipment #HighThroughput #HealthcareInnovation #CustomSolutions #R&DExcellence

0 notes

hariganesh858 · 16 days ago

Text

Cell Culture Protein Surface Coating Market

Cell Culture Protein Surface Coating Market Size, Share, Trends: Corning Incorporated Leads

Growing Use of 3D Cell Cultures for Drug Research and Tissue Engineering

Market Overview:

The global Cell Culture Protein Surface Coating Market is expected to increase at a compound annual growth rate (CAGR) of 12.5%, reaching USD 1.8 billion by 2031 from USD 789.5 million in 2022. North America is the industry leader because of its high level of research effort and concentration of major biotechnology businesses. The demand for cell-based research is expanding, and 3D cell culture technological advancements and increased funding for stem cell research are driving this growth in the Cell Culture Protein Surface Coating market. The increasing usage of cell culture techniques in response to the increased awareness of regenerative therapies and customised medicine highlights the need for protein surface coatings. Further driving market expansion are the growing biopharmaceutical sector and the move towards chemically defined, animal-free manufacturing processes.

DOWNLOAD FREE SAMPLE

Market Trends:

Driven by the need for increased reproducibility, safety, and regulatory compliance, the cell culture industry is clearly moving toward chemically defined and xeno-free culture techniques. This tendency is seriously influencing the cell culture protein surface coating industry. Conventional animal-derived coatings like collagen and fibronectin are being replaced more and more by synthetic and recombinant replacements. Among its many advantages are batch-to-batch homogeneity, less risk of contamination, and better control of cell activity by means of these chemically defined coatings. Moreover, xeno-free coatings eliminate problems regarding animal-derived components, so they are ideal for clinical applications and stem cell research.

Market Segmentation:

Pre-coated surfaces lead the cell culture protein surface coating industry as they provide researchers ready-to-use, consistent solutions saving time. By eliminating the need for internal coating processes and hence reducing variance, these products increase experimental reproducibility. Pre-coated surfaces are particularly sought after in applications such high-throughput screening and routine cell culture operations, where uniformity and efficiency are absolutely critical. Customized pre-coated products that fit certain cell types and research goals are becoming available, thus meeting the many needs of the scientific community and therefore boosting the segment's predominance.

Market Key Players:

The Cell Culture Protein Surface Coating sector is characterized by constantly innovative ideas and fierce competition. Important companies are focusing on developing novel coating formulations, expanding their product lines, and raising their geographical presence by means of strategic partnerships and acquisitions. Key companies such as Corning Incorporated, Thermo Fisher Scientific Inc., Merck KGaA, Sigma-Aldrich Corporation, BioLamina AB, Roche Diagnostics, EMD Millipore, Bio-Techne Corporation, PerkinElmer Inc., and Biomedical Structures LLC dominate the market.

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market research #market trends

0 notes

roshankumar7904800 · 16 days ago

Text

Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitor Market Size, Share, Trends: Novartis AG Leads

Rising Cancer Incidence Drives Demand for Targeted Therapies

Market Overview:

The global tyrosine kinase inhibitor market is expected to develop at a 7.8% CAGR from 2024 to 2031. The market will grow from USD XX billion in 2024 to USD YY billion by 2031. North America currently dominates the market owing to its high cancer prevalence and robust healthcare infrastructure. Key criteria include increased R&D investments, rising cancer incidence rates, and growing use of targeted medicines. The market is expanding rapidly because of the rising frequency of cancer and other chronic diseases, advances in drug discovery technologies, and a growing emphasis on personalised treatment. The growing pipeline of tyrosine kinase inhibitors, together with their proven efficacy in treating various forms of cancer, is driving market expansion.

DOWNLOAD FREE SAMPLE

Market Trends:

The global rise in cancer diagnoses is driving the need for more effective and targeted treatments. Tyrosine kinase inhibitors have demonstrated great efficacy in treating a variety of cancers, including lung, breast, and leukaemia. The World Health Organisation predicts that the number of new cancer cases will increase by 60% by 2040, presenting a significant market opportunity for tyrosine kinase inhibitors. Technological breakthroughs in medication discovery and development are hastening the introduction of new tyrosine kinase inhibitors. High-throughput screening, computer-aided drug design, and a better understanding of cancer biology have enabled the development of more selective and powerful inhibitors.

Market Segmentation:

Receptor Tyrosine Kinase Inhibitors now dominate the Tyrosine Kinase Inhibitors market. This segment's dominance is due to the large spectrum of cancer types that these inhibitors can target, such as non-small cell lung cancer, breast cancer, and renal cell carcinoma. The effectiveness of medications such as erlotinib, gefitinib, and sunitinib in treating these prevalent malignancies has resulted in their widespread use. Recent clinical trials have yielded promising outcomes for next-generation receptor tyrosine kinase inhibitors. A phase III trial of selpercatinib, a highly selective RET inhibitor, revealed a 64% objective response rate in patients with RET fusion-positive non-small cell lung cancer.

Market Key Players:

The tyrosine kinase inhibitor market is highly competitive, with top competitors focussing on innovation and strategic collaborations. Key companies such as Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, and Eli Lilly and Company dominate the market.

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market research #market trends

0 notes

global-research-report · 18 days ago

Text

Trends in the Laboratory Centrifuges Market

The global laboratory centrifuges market size was estimated at USD 1.73 billion in 2023 and is projected to grow at a CAGR of 5.70% from 2024 to 2030 due to advancements in application and increased research activities. Laboratory centrifuge is essential in separating mixtures based on density, making them crucial in various fields such as biotechnology, pharmaceuticals, and clinical diagnostics.

The increasing demand for personalized medicine and advancements in genomics and proteomics is anticipated to fuel the demand for centrifuge equipment. Moreover, the rise in the prevalence of chronic diseases, growing diagnostic testing, and increasing developments of advanced products are anticipated to propel the market growth in the coming years. For instance, in February 2022, Beckman Coulter Life Sciences introduced the Allegra V-15R Benchtop Centrifuge. This new model has ten rotor configurations and 50 programmable runs, complemented by a wide range of adapters. Its versatile design enables a variety of workflows and model types, including blood separation and high-throughput screening.

Furthermore, technological advancements are anticipated to influence the laboratory centrifuges market over the forecast period. Innovations such as automated and high-speed centrifuges have improved efficiency and accuracy, which are critical in laboratory settings. The development of compact and user-friendly models has also made these devices more accessible to smaller labs and research facilities. For instance, in April 2021, Eppendorf launched the Centrifuge 5910 Ri, a new model designed to boost laboratory efficiency. This centrifuge offers scientists advanced features to streamline and expedite their workflow. Its innovative touchscreen interface allows for rapid parameter settings, while three levels of user management options enhance security and traceability. Such technological advancements and novel developments are anticipated to drive the laboratory centrifuges market.

Laboratory Centrifuges Market Segment Highlights

The equipment segment held the largest share of 82.63% in 2023, driven by advancements in technology and the growing focus of key industry participants on developing novel equipment.

The floor-standing centrifuge segment held the largest share of 54.88% in 2023, driven by advancements in technology and continuous innovation.

The clinical centrifuge segment dominated the market with a share of 45.78% in 2023. The clinical centrifuge market is a rapidly growing sector of the healthcare industry, driven by the increasing demand for accurate and efficient diagnostic testing in hospitals, research laboratories, and clinical settings.

The microbiology segment held the largest share of 34.3% in 2023. Due to the growing need for rapid and accurate detection of microorganisms in various applications such as clinical diagnostics, pharmaceutical research, and food safety testing.

Global Laboratory Centrifuges Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the laboratory centrifuges market report on the basis of product, intended use, application, model, and region.

Product Outlook (Revenue, USD Million, 2018 - 2030)

Equipment

Accessories

Model Outlook (Revenue, USD Million, 2018 - 2030)

Floor-Standing Centrifuges

Benchtop Centrifuges

Intended Use Outlook (Revenue, USD Million, 2018 - 2030)

Clinical Centrifuges

Preclinical Centrifuges

General Purpose Centrifuges

Application Outlook (Revenue, USD Million, 2018 - 2030)

Microbiology

Cellomics

Proteomics

Diagnostics

Genomics

Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Canada

Mexico

Europe

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Argentina

Brazil

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Order a free sample PDF of the Laboratory Centrifuges Market Intelligence Study, published by Grand View Research.

#Laboratory Centrifuges Market

0 notes

willyskristina · 24 days ago

Text

Apoptosis Assays Market

Apoptosis Assays Market Size, Share, Trends: Thermo Fisher Scientific Inc. Leads

Shift Towards Multiplexed and High-Throughput Apoptosis Assays for Comprehensive Cell Death Analysis

Market Overview:

The global apoptosis assays market is expected to develop at a CAGR of 8.2% between 2024 and 2031. North America now dominates the market, accounting for over 35% of total worldwide share. Key metrics include the expanding prevalence of chronic diseases, increased R&D investments in drug discovery, and the growing use of high-throughput screening techniques.

The Apoptosis Assays Market is expanding rapidly, owing to a growing emphasis on personalised treatment and increased need for targeted cancer medicines. The market is seeing an increase in technological improvements, particularly in flow cytometry and high-content screening technologies, which improve the accuracy and efficiency of apoptosis detection. Furthermore, the rising uses of apoptosis tests in stem cell research and regenerative medicine are creating new opportunities for market growth.

DOWNLOAD FREE SAMPLE

Market Trends:

The Apoptosis Assays Market is seeing a substantial shift towards multiplexed and high-throughput assays, driven by the need for more thorough and efficient cell death studies. This shift allows researchers to assess several apoptotic characteristics, such as caspase activation, mitochondrial membrane potential, and DNA fragmentation, in a single experiment. The use of sophisticated assays is especially prevalent in drug discovery and development processes, where rapid and reliable screening of vast chemical libraries is essential.

For example, a recent study in the Journal of Biomolecular Screening found that using multiplexed apoptosis assays in high-throughput screening campaigns resulted in a 40% reduction in false positives when compared to standard single-parameter assays. This increase in accuracy and efficiency is fuelling demand for multiplexed apoptosis assay kits and reagents. Furthermore, the use of artificial intelligence and machine learning algorithms in data analysis improves the interpretation of complicated apoptotic information, allowing researchers to detect subtle trends and prospective treatment candidates more efficiently.

The move towards multiplexed and high-throughput apoptosis testing is encouraging collaborations between academic institutions and pharmaceutical businesses. These collaborations aim to create new test formats and broaden the usage of apoptosis assays in fields like immunology and neurodegenerative disease research. As a result, the market is seeing a boom in product innovation, with several major manufacturers releasing next-generation apoptosis detection platforms with higher sensitivity, repeatability, and throughput.

Market Segmentation:

Caspase assays dominate the Apoptosis Assays Market, accounting for approximately 40% of the market share in 2023. Caspase assays have emerged as the leading sector in the Apoptosis Assays Market, owing to their high specificity and sensitivity in detecting important hallmarks of programmed cell death. These assays are essential for a variety of applications, including drug development, toxicity assessment, and fundamental cell biology research. Caspase assays dominate because of their versatility in detecting both early and late phases of apoptosis, as well as their compatibility with a variety of detection platforms.

Recent advances in caspase assay technologies have strengthened their commercial position. For example, the advent of real-time caspase assays has allowed researchers to track apoptosis dynamics in live cells, providing important insights into the temporal features of cell death. A study published in Nature Methods found that real-time caspase tests might identify apoptosis initiation up to 4 hours sooner than standard end-point assays, considerably increasing the sensitivity of drug screening programs.

The pharmaceutical sector has been a major driver of the caspase assays segment, with a growing number of drug discovery programs including these assays into their screening processes. Over 60% of oncology drug discovery projects currently use caspase-based assays in their early-stage chemical screening processes, according to Biotechnology Innovation Organisation (BIO) research. The importance of apoptosis in cancer progression, as well as the possibility of caspase-targeted medicines in cancer treatment, are driving this widespread acceptance. Furthermore, the combination of caspase assays and high-content imaging systems has created new opportunities for multiplexed investigation of apoptotic processes. Leading life science businesses reported a 30% year-over-year increase in multiplexed caspase assay kit sales, indicating a growing demand for complete apoptosis profiling in university and industrial research contexts. This tendency is projected to continue driving the caspase assays segment further in the coming years.

Market Key Players:

Thermo Fisher Scientific Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Becton, Dickinson and Company

Abcam plc

Promega Corporation

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market growth #market trends

0 notes

shadyzombieanchor · 1 month ago

Link

0 notes

jayanthitbrc · 2 months ago

Text

Future of High Throughput Screening (HTS) Market Innovations and Global Market Trends

The high throughput screening (hts) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

High Throughput Screening (HTS) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The high throughput screening market size has grown rapidly in recent years. It will grow from $20.66 billion in 2023 to $22.98 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing adoption of high-throughput screening, rising r&d spending, growing availability of funds for research, increasing healthcare spending, competitive market landscape.

The high throughput screening market size is expected to see strong growth in the next few years. It will grow to $33.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing market size and growth rate, strategic developments by key players, rising demand for disease monitoring and drug discovery, rising prevalence of chronic diseases, growing focus towards implementation of ultra high throughput screening (UHTS) techniques. Major trends in the forecast period include technological advancements in high-throughput screening, growing focus towards implementation of ultra high throughput screening (UHTS) techniques.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/high-throughput-screening-hts-global-market-report

Scope Of High Throughput Screening (HTS) Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

High Throughput Screening (HTS) Market Overview

Market Drivers - The rise in the prevalence of chronic diseases is expected to propel the growth of the high-throughput screening (HTS) market going forward. Chronic disease refers to a long-term health condition or disease that persists over an extended period, typically lasting for three months or more. HTS enables rapid screening of numerous chemical compounds to pinpoint potential drug candidates targeting specific pathways or mechanisms implicated in chronic diseases, essential for their effective long-term management For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based medical library run by the federal government, the number of people aged 50 and older with one or more chronic diseases is expected to increase by 99.5%, totaling 142.66 million by 2050, compared to 71.522 million in 2020 in the United States of America. Therefore, the rise in the prevalence of chronic diseases will drive the growth of the high-throughput screening (HTS) market.

Market Trends - Major companies operating in the high-throughput screening market are developing innovative products, such as multimode plate readers, to better serve their customers with advanced features. A multimode plate reader (MPR) is an advanced lab tool used in high-throughput screening, analyzing biological and chemical samples in microplates by integrating multiple detection modes for diverse assays within a single platform. For instance, in February 2023, PerkinElmer Inc., a US-based MedTech company, launched the EnVision Nexus system. The EnVision Nexus system stands out as the fastest and most sensitive multimode plate reader available, explicitly designed for demanding high-throughput screening (HTS) applications to expedite drug discovery efforts. With its unique technology, including dual detectors and optimized reagents like proprietary HTRF and AlphaLISA, coupled with the latest reagent kits, the platform offers researchers unparalleled assay flexibility, accuracy, speed, and sensitivity. Equipped with walkaway convenience options such as a plate stacker for 20 or 50 plates or full automation and integration for continuous 24/7 workflow-driven operations, the EnVision Nexus system empowers researchers to efficiently screen millions of samples with unprecedented efficiency.

The high throughput screening (HTS) market covered in this report is segmented –

1) By Products And Services: Consumables And Reagents, Instruments, Software And Services 2) By Technology: Ultra-High-Throughput Screening, Cell-Based Assays, Lab-on-a-chip, Label-Free Technology 3) By Application: Target Identification And Validation, Primary And Secondary Screening, Toxicology Assessment, Other Applications 4) By End User: Pharmaceuticals And Biotechnology Industry, Academics And Research Institute, Contract Research Organization, Other End Users

Get an inside scoop of the high throughput screening (hts) market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=14116&type=smp

Regional Insights - North America was the largest region in the high throughput screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the high throughput screening (HTS) market are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc., Biomat Srl, Diana Biotechnologies s.r.o

Table of Contents 1. Executive Summary 2. High Throughput Screening (HTS) Market Report Structure 3. High Throughput Screening (HTS) Market Trends And Strategies 4. High Throughput Screening (HTS) Market – Macro Economic Scenario 5. High Throughput Screening (HTS) Market Size And Growth ….. 27. High Throughput Screening (HTS) Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

credenceresearchdotblog · 2 months ago

Text

The fragment-based drug discovery (FBDD) market is projected to grow from USD 1,220 million in 2024 to an estimated USD 2,935.44 million by 2032, registering a robust compound annual growth rate (CAGR) of 11.6% over the forecast period. Fragment-Based Drug Discovery (FBDD) is an innovative and rapidly growing approach in the field of drug discovery. Unlike traditional high-throughput screening (HTS) methods, which test large libraries of compounds for potential drug candidates, FBDD focuses on small, low-molecular-weight compounds, known as fragments. These fragments are considered to be the building blocks for larger, more complex drugs and offer several advantages in terms of efficiency, cost, and the ability to target challenging disease proteins.FBDD is a screening method that identifies small, low molecular weight compounds (fragments) which bind weakly to a biological target, often a protein involved in disease. These fragments are then optimized into potent drug candidates through various medicinal chemistry techniques. The key advantage of FBDD over traditional drug discovery methods is its ability to explore a broader chemical space and target complex proteins that are often considered undruggable by conventional methods.

Browse the full report https://www.credenceresearch.com/report/fragment-based-drug-discovery-market

Market Overview

The FBDD market has been witnessing robust growth, driven by the increasing need for more efficient drug discovery methods, especially for complex and previously "undruggable" targets. The global market for FBDD is expected to grow substantially in the coming years, supported by advancements in screening technologies, growing investment in biotechnology, and an increasing focus on precision medicine.

In 2023, the global FBDD market was valued at approximately $500 million and is projected to expand at a compound annual growth rate (CAGR) of around 12% from 2024 to 2030. This growth is attributed to factors such as the rising demand for novel therapeutics in areas like oncology, neuroscience, and infectious diseases, where traditional drug discovery methods often fall short.

Drivers of FBDD Market Growth

1. Rising Demand for Targeting Complex Diseases: Traditional drug discovery techniques often struggle to address diseases driven by difficult-to-target proteins, including cancers, neurodegenerative diseases, and infectious diseases. FBDD, with its ability to work with small molecules, offers a promising solution for developing drugs that can interact with these complex targets. 2. Technological Advancements in Screening Techniques: The development of powerful screening technologies, such as cryo-electron microscopy (cryo-EM), NMR spectroscopy, and SPR, has significantly improved the efficiency and accuracy of fragment screening. These technologies have enhanced the identification of fragment hits, allowing for quicker and more reliable drug discovery processes.

3. Collaborations and Partnerships: Pharmaceutical companies and biotech firms are increasingly collaborating with contract research organizations (CROs) and academic institutions to leverage expertise in fragment-based screening. These collaborations foster innovation, reduce time-to-market for new drugs, and drive competition in the FBDD space.

4. Cost-Effectiveness: FBDD allows for the exploration of vast chemical space with fewer resources compared to traditional high-throughput screening methods. This makes it an attractive option for both large pharmaceutical companies and smaller biotech firms looking to optimize their drug discovery pipelines.

Challenges Facing the FBDD Market

While the FBDD market is growing, it does face several challenges: 1. Fragment Hit Optimization: The process of optimizing fragments into potent drug candidates can be time-consuming and expensive. Despite the ability to identify binding fragments early, the path from fragment to drug can involve substantial trial and error. 2. Limited Fragment Libraries: Although there has been significant progress in creating fragment libraries, these libraries still remain limited compared to the enormous chemical space that needs to be explored. Expanding these libraries is critical for further improving FBDD's success rate.

3. Regulatory and Safety Concerns: As with any new drug discovery technique, regulatory hurdles and safety concerns regarding the potential side effects of drugs developed using FBDD remain an ongoing challenge. Ensuring that FBDD-derived drugs are safe and effective in humans requires rigorous preclinical and clinical testing.

Future Outlook

Despite these challenges, the future of the FBDD market looks promising. Ongoing advancements in screening technologies, along with increased collaboration between industry players and academia, are expected to overcome current limitations. Furthermore, as the pharmaceutical industry continues to push for more targeted and personalized treatments, FBDD will play a crucial role in developing drugs that can tackle previously untreatable diseases.

The expanding focus on precision medicine, which aims to tailor treatments based on individual genetic profiles, further boosts the demand for FBDD as it provides the ability to create highly specific drugs for diverse patient populations. As the pharmaceutical industry becomes more data-driven and personalized, FBDD’s potential in revolutionizing drug discovery will continue to grow.

Key Player Analysis:

Astex Pharmaceuticals, Inc.

Alveus Pharmaceuticals Pvt. Ltd.

Beactica Therapeutics AB

Charles River Laboratories International, Inc.

Crown Bioscience, Inc.

Evotec SE

Kinetic Discovery Limited

Proteros biostructures GmbH

Sprint Bioscience AB

Sygnature Discovery

Segmentations:

By Component

Fragment Screening

Biophysical Techniques

NMR Spectroscopy

Differential Scanning Fluorimetry (DSF) Assay

Fluorescence Polarization

Isothermal Titration Calorimetry

X-ray Crystallography

Surface Plasmon Resonance (SPR)

Bilayer Interferometry

Mass Spectrometry (MS)

Capillary Electrophoresis

Weak Affinity Chromatography (WAC – HPLC-UV/MS)

Other assays (biochemical)

Non-biophysical Techniques

Fragment Optimization

By Application

Oncology

Central Nervous System (CNS) Disorders

Infectious Diseases

Cardiovascular Diseases

Metabolic Disorders

Inflammation & Autoimmune Diseases

By End-user

Academic & Research Institutions

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

By Regions

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/fragment-based-drug-discovery-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

marketanalysisdata · 2 months ago

Text

Blood Screening Market Emerging Trends, Analysis and Forecasts 2030

The global blood screening market was valued at USD 3.40 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. This growth is primarily driven by an increasing number of blood donations worldwide, which requires stringent screening protocols to prevent the transmission of infections through transfusions. Technological advancements, particularly in automation and molecular diagnostic platforms, have improved both the efficiency and accuracy of blood screening processes. Additionally, the rising prevalence of infectious diseases and government-backed initiatives promoting blood safety contribute to this market expansion. There is also growing public awareness about the importance of safe blood transfusions, which further supports market growth.

Blood screening is an essential medical process in which blood samples are analyzed to identify health conditions and potential abnormalities. This diagnostic tool provides crucial insights into a person’s health status, helping detect, prevent, and manage various diseases at an early stage. Blood screening involves assessing blood cell counts, identifying infectious agents like viruses and bacteria, and measuring specific chemical levels, such as cholesterol and glucose. The value of blood screening lies in its ability to allow healthcare providers to detect health issues before symptoms become evident, making it a critical tool for diagnosing conditions such as anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Ongoing technological innovations have significantly enhanced the precision and efficiency of screening techniques. Moreover, increased awareness about the benefits of early disease detection has led to a greater emphasis on preventive healthcare practices. The aging global population also contributes to demand growth, as the prevalence of age-related conditions that require regular blood screening rises.

In addition, rising global healthcare expenditures support the adoption of advanced technologies and services within blood screening, as healthcare providers seek to implement the latest and most effective diagnostic tools. These factors collectively fuel the growth and development of the blood screening market, highlighting its role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Technology Segmentation Insights:

Nucleic Acid Amplification Tests (NAT) led the blood screening market, capturing a revenue share of 41.2% in 2024. The high demand for NAT is attributed to the increasing prevalence of infectious diseases, such as HIV and hepatitis, which require accurate and rapid testing that NAT provides. NAT tests are known for their high sensitivity and specificity, enabling them to detect even low levels of viral loads that traditional methods may not identify. The rising demand for early disease diagnosis and monitoring further propels the adoption of NAT. Technological improvements in amplification techniques also enhance the speed and efficiency of these tests, making them more suitable for use in clinical settings.

Next Generation Sequencing (NGS) is expected to grow at a CAGR of 16.5% over the forecast period. This technology has transformed genomic analysis by dramatically lowering sequencing costs while increasing accuracy. NGS allows for comprehensive profiling of genetic mutations, which is essential for personalized medicine and targeted therapies. Additionally, NGS’s ability to process multiple samples simultaneously increases laboratory throughput, making it an appealing choice for healthcare providers. The continuous advancements in NGS technologies ensure their relevance in applications such as early disease detection and monitoring, which supports market growth.

Overall, the development and adoption of advanced blood screening technologies like NAT and NGS drive the market’s expansion, underscoring their importance in delivering accurate, timely, and personalized healthcare solutions.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Analysis #Blood Screening Market Trends #Blood Screening Market Growth

0 notes

marketstudyreport · 2 months ago

Text

Blood Screening Market Strategies With Forecast Till 2030

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technology Segmentation Insights:

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Analysis #Blood Screening Market Trends #Blood Screening Market Growth

0 notes

datalyst · 2 months ago

Text

The Molecular Diagnostics Market: A Deep Dive into Precision Medicine and Technological Advancements

The Molecular Diagnostics Market has emerged as a critical player, driving advancements in precision medicine. This sector's ability to provide specific, reliable, and real-time data at the molecular level has accelerated the development of personalized treatments, enabling clinicians to diagnose diseases earlier and more accurately. From its foundation in genomics to its expanding applications across oncology, infectious diseases, and genetic testing, the molecular diagnostics market is witnessing rapid growth. This blog will explore the molecular diagnostics landscape, its primary technologies, industry growth drivers, and key challenges.

Understanding Molecular Diagnostics

Molecular diagnostics is a field that focuses on analyzing biological markers in the genome and proteome—the individual’s genetic code and how cells express their genes. These diagnostics provide insights into the molecular underpinnings of disease, often involving DNA or RNA detection to understand the health status or predisposition to specific conditions. Unlike traditional diagnostics, molecular diagnostics reveals the root cause at the molecular level, allowing for precise interventions tailored to the patient.

Major Segments in Molecular Diagnostics

The molecular diagnostics market encompasses several segments based on technologies, applications, end-users, and regions.

Technology Key technologies in molecular diagnostics include Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), DNA Microarrays, and In Situ Hybridization (ISH). PCR remains a staple in molecular testing for its simplicity and efficiency, while NGS has unlocked unprecedented possibilities in genomic testing. DNA microarrays, once the go-to technology, continue to play a role in specialized applications, particularly when high-throughput screening is necessary.

Application Applications in molecular diagnostics are vast, with significant focus areas in oncology, infectious disease testing, genetic testing, and pharmacogenomics. Oncology has been one of the fastest-growing applications, given the increasing prevalence of cancers worldwide. In infectious disease testing, molecular diagnostics was instrumental in managing the COVID-19 pandemic, bringing global attention to its capabilities. Genetic testing, which includes prenatal testing and newborn screening, is another vital segment, especially as it enables early disease detection and the potential for preventive care.

End-Users Molecular diagnostics primarily serves hospitals, diagnostic laboratories, academic and research institutes, and even home healthcare setups. Hospitals and diagnostic laboratories account for the highest share due to the need for advanced equipment, high-volume testing, and expert personnel.

The Growth Dynamics of the Molecular Diagnostics Market

The global molecular diagnostics market is projected to grow significantly in the coming years, driven by various factors:

Rising Incidences of Chronic and Infectious Diseases Chronic diseases like cancer, cardiovascular diseases, and diabetes are on the rise globally. Molecular diagnostics enables earlier and more accurate diagnosis, facilitating timely and targeted treatment. Similarly, infectious diseases—such as HIV, hepatitis, tuberculosis, and, more recently, COVID-19—require rapid diagnosis, which molecular diagnostics can deliver with high precision.

Expansion of Precision Medicine Precision medicine, which focuses on tailoring treatment to the individual, has been a major growth driver. Molecular diagnostics enables the identification of patient-specific mutations and disease markers, leading to personalized treatment plans that improve outcomes. The ability to select targeted therapies is particularly significant in cancer treatment, where one-size-fits-all approaches often fall short.

Technological Advancements The molecular diagnostics market has benefited tremendously from technological advancements. The introduction of digital PCR, automated and high-throughput NGS platforms, and enhanced bioinformatics tools has increased testing speed, accuracy, and affordability. Additionally, advancements in artificial intelligence (AI) and machine learning are enabling better data analysis, predictive modeling, and decision-making.

Growing Demand for Point-of-Care Diagnostics Point-of-care (POC) diagnostics allow for on-the-spot testing, often in non-laboratory environments, which can be particularly valuable in managing diseases in remote or underserved areas. As molecular diagnostics advances in miniaturization and automation, point-of-care molecular tests are becoming increasingly feasible, allowing for broader deployment.

Key Technologies Shaping Molecular Diagnostics

Polymerase Chain Reaction (PCR) PCR is a cornerstone of molecular diagnostics, offering simplicity, rapidity, and affordability. Real-time PCR (qPCR) and reverse-transcriptase PCR (RT-PCR) have been widely used, especially in infectious disease testing. The COVID-19 pandemic highlighted PCR's importance, demonstrating its ability to provide accurate and rapid results.

Next-Generation Sequencing (NGS) NGS enables comprehensive genetic analysis, allowing for the simultaneous sequencing of millions of DNA strands. NGS is pivotal in oncology, where it identifies specific mutations associated with cancers. In infectious disease control, NGS helps trace pathogens and track mutations, proving invaluable in managing outbreaks.

CRISPR-based Diagnostics Though still emerging, CRISPR technology is beginning to influence the molecular diagnostics space, especially in infectious disease detection. CRISPR diagnostics leverages gene-editing technology to identify specific DNA or RNA sequences, offering a high level of precision. CRISPR diagnostics are fast, cost-effective, and highly specific, showing promise in point-of-care settings.

Digital PCR Digital PCR has taken PCR a step further by providing higher accuracy and sensitivity, making it ideal for detecting low-abundance DNA or RNA targets. Digital PCR is particularly useful in cancer mutation testing, where detecting rare mutations or quantifying gene expression levels is necessary.

The Role of Bioinformatics in Molecular Diagnostics

As molecular diagnostics involves analyzing large and complex datasets, bioinformatics has become indispensable. Advanced bioinformatics tools enable faster and more accurate analysis of NGS data, aiding in identifying disease markers, understanding drug resistance mechanisms, and providing clinical decision support. With the integration of AI, bioinformatics tools are evolving to predict disease outcomes, identify patient responses to treatment, and suggest targeted therapies, marking a shift toward predictive diagnostics.

Regional Insights: Global Reach of Molecular Diagnostics

The molecular diagnostics market has established a global presence, with key regions contributing uniquely:

North America is the largest market due to high healthcare spending, advanced infrastructure, and early adoption of cutting-edge technologies.

Europe is significant, driven by high incidences of chronic diseases and government support for molecular diagnostics in preventive care.

Asia-Pacific is the fastest-growing region due to rising healthcare awareness, improving infrastructure, and increasing incidences of infectious diseases. China and India are leading this growth, with a particular focus on infectious disease testing.

Latin America and the Middle East & Africa are also developing markets, with gradual adoption of molecular diagnostics.

Challenges and Future Prospects

Despite its growth, the molecular diagnostics market faces challenges, including:

High Costs The initial setup and ongoing operational costs for molecular diagnostics can be prohibitive, particularly in low-resource settings. Although prices have gradually decreased, high-end equipment like NGS systems remains costly.

Regulatory Hurdles Regulatory approval for molecular diagnostics is rigorous, ensuring safety and efficacy. However, the process can be lengthy, especially for innovative technologies like CRISPR and digital PCR.

Skilled Personnel Shortage Running molecular diagnostic tests often requires skilled personnel, limiting the technology's reach in rural and remote areas. Automated and point-of-care devices are gradually addressing this gap, but more workforce training is necessary.

The Road Ahead for Molecular Diagnostics

The future of molecular diagnostics looks promising, with an increasing shift toward preventive and personalized medicine. The integration of digital health tools, AI, and wearable diagnostics is set to enhance the speed and accessibility of molecular testing. Additionally, as sequencing technology becomes more cost-effective, its adoption in routine diagnostics will likely increase, bringing precision medicine to a broader population.

Pharmaceutical and biotech companies are also investing heavily in molecular diagnostics research, especially in companion diagnostics that guide drug development. This partnership between diagnostics and therapeutics will likely yield personalized, effective treatments that reduce side effects and improve patient outcomes.

Conclusion

The molecular diagnostics market is at the forefront of a healthcare transformation, spearheading a shift from reactive to proactive medicine. With its ability to diagnose diseases at the genetic level, tailor treatments to individual patients, and predict disease trajectories, molecular diagnostics is enabling a more personalized and effective healthcare system. The next decade promises even greater advancements, making molecular diagnostics an exciting field poised to redefine how we understand and treat disease.

0 notes

farmacuticals · 2 months ago

Text

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

0 notes

global-research-report · 21 days ago

Text

Global Induced Pluripotent Stem Cells Market: Opportunities in Drug Development and Disease Treatment

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights

By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.

By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.

By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.

North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Induced Pluripotent Stem Cells Market Segmentation

Grand View Research has segmented the global induced pluripotent stem cells market based on derived cell type, application, end-use, and region:

Induced Pluripotent Stem Cells Derived Cell Type Outlook (Revenue, USD Million, 2018 - 2030)

Hepatocytes

Fibroblasts

Keratinocytes

Amniotic Cells

Others

Induced Pluripotent Stem Cells Application Outlook (Revenue, USD Million, 2018 - 2030)

Drug Development

Tissue Engineering & Regenerative Medicine

Neurology

Orthopedics

Oncology

Cardiovascular and Myocardial Infraction

Diabetes

Others

Toxicology Research

Disease Modeling

Induced Pluripotent Stem Cells End-use Outlook (Revenue, USD Million, 2018 - 2030)

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Others

Induced Pluripotent Stem Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Canada

Mexico

Europe

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Order a free sample PDF of the Induced Pluripotent Stem Cells Market Intelligence Study, published by Grand View Research.

#Induced Pluripotent Stem Cells Market

0 notes

willyskristina · 25 days ago

Text

Compound Management

Compound Management Market Size, Share, Trends: Brooks Automation Leads

Integration of Artificial Intelligence and Machine Learning in Compound Management Systems Revolutionizes Sample Tracking and Analysis

Market Overview:

The global compound management market is projected to grow at a CAGR of 14.2% from 2024 to 2031, reaching USD 724.3 million by 2031. North America dominates the market due to increasing drug discovery activities, rising demand for outsourcing compound management services, and the growing adoption of automated compound management systems. The market is expanding rapidly, driven by the increasing complexity of drug development procedures, the growing number of drug candidates in pharmaceutical pipelines, and the need for efficient storage and retrieval of chemical and biological samples. There is a significant transition to automated methods and integrated software solutions to enhance productivity and reduce human error in compound library management.

DOWNLOAD FREE SAMPLE

Market Trends:

The compound management industry is witnessing a significant shift towards intelligent systems, driven by the integration of artificial intelligence (AI) and machine learning (ML) technologies. These technologies are revolutionizing sample tracking and analysis, with companies investing in smart compound management platforms that can predict sample degradation, optimize storage conditions, and streamline retrieval processes. For example, Brooks Life Sciences' BioStore III Cryo automated storage system uses AI algorithms to predict and prevent sample integrity issues. This trend is further supported by the rising demand for predictive analytics in drug discovery.

Market Segmentation:

Chemical compounds dominate the compound management market, accounting for a significant share due to the widespread use of small molecule libraries in drug discovery and development. The segment has seen substantial progress thanks to innovations in storage technologies, sample tracking systems, and integration with high-throughput screening platforms. Efficient management of chemical compound libraries is crucial for expediting drug discovery. Advanced compound management systems allow researchers to store, retrieve, and track millions of compounds efficiently, reducing the time and cost of early-stage drug development. The growth of DNA-encoded libraries (DELs) has further increased the demand for advanced chemical compound management solutions.

Market Key Players:

Brooks Automation (Azenta Life Sciences)

Hamilton Company

TTP Labtech (SPT Labtech)

Tecan Group

Evotec

Titian Software

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market growth #market insights #market trends

0 notes